
Financial Results for FY2018 & Outlook for FY2019



(Cautionary Statement)

Statements made in this material with respect to Sumitomo Chemical's current plans, estimates, strategies and beliefs that are not historical facts are forward-looking statements about the future performance of Sumitomo Chemical. These statements are based on management's assumptions and beliefs in light of the information currently available to it, and involve risks and uncertainties. The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in Sumitomo Chemical's markets; demand for, and competitive pricing pressure on, Sumitomo Chemical's products in the marketplace; Sumitomo Chemical's ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.

Contents

1. Consolidated Financial Results for FY2018 Ended March 31, 2019

Financial Summary	4
Sales revenue by Business segment · · · · · · · · · ·	5
Core Operating Income by Business segment · · · ·	6
Segment Analysis · · · · · · · · · · · · · · · · · ·	7
Breakdown of Non-recurring Items · · · · · · · · · · · · · · · · · · ·	12
Consolidated Balance Sheets · · · · · · · · · · · · · · · · · · ·	13
Consolidated Statements of Cash Flows · · · · · ·	14

2. Outlook for FY2019

Financial Summary	16
Sales revenue by Business segment · · · · · · · · ·	17
Core Operating Income by Business segment \cdots	18
Segment Analysis · · · · · · · · · · · · · · · · · ·	19
Consolidated Statements of Cash Flows · · · · · · ·	24

(Reference: Segment Information)

Segment Topics · · · · · · · · · · · · · · · · · · ·	26
Sales revenue by Business segment (Quarterly)······	27
Core Operating Income by Business segment (Quarterly)······	28
Cost Elements etc.	29
Capital Expenditures by Business segment · · · · · · ·	30
Estimated Capital Expenditures by Business segment ·····	31
Depreciation and Amortization by Business segment · · · · · · · · · · · · · · · · · · ·	32
Estimated Depreciation and Amortization	
by Business segment	33
Research & Development Expenses by Business segment · · · · · · · · · · · · · · · · · · ·	34
Estimated Research & Development Expenses by Business segment · · · · · · · · · · · · · · · · · · ·	35
Major Group Companies · · · · · · · · · · · · · · · · · · ·	36
Overseas Sales revenue ······	37
Sales revenue / Profits Transition · · · · · · · · · · · · · · · · · · ·	38
Interest-bearing Liabilities / D/E Ratio Transition · · · · ·	39
Cash Dividends / Payout Ratio Transition	40



1. Consolidated Financial Results for FY2018 Ended March 31, 2019



Financial Summary


Unit; billions						
	FY2017	FY2018	Difference	Ratio		
Sales revenue	2,190.5	2,318.6	128.1	5.8%		
Core operating income	262.7	204.3	-58.4	-22.2%		
(Equity in earnings)	(55.3)	(37.2)	(-18.1)	-		
Non-recurring items	-11.8	-21.3	-9.5	-		
Operating income	250.9	183.0	-68.0	-27.1%		
Finance income/expenses	-10.1	5.4	15.5	-		
(Gain/loss on foreign currency transactions)	(-9.6)	(5.5)	(15.1)			
Income tax expenses	-62.7	-35.9	26.7	-		
Net income attributable to non-controlling interests	-44.4	-34.5	9.9	-		
Net income attributable to owners of the parent	133.8	118.0	-15.8	-11.8%		
ROE	15.4%	12.3%				
Exchange rate(yen/\$)	110.85	110.92				
Naphtha price(yen/KL)	41,900	49,500				
Overseas sales revenue ratio	63.2%	64.9%				



Sales revenue by Business segment

	FY2017	FY2018	Difference	Ratio	Sales Price Variance	Shipping Volume Variance	Foreign Currency Conversion Variance
Petrochemicals & Plastics	674.1	757.5	83.4	12.4%	29.5	53.9	0.0
Energy & Functional Materials	251.0	282.9	31.9	12.7%	9.0	23.1	-0.2
IT-related Chemicals	368.7	396.8	28.1	7.6%	-10.0	41.5	-3.4
Health & Crop Sciences	339.7	338.1	-1.6	-0.5%	-5.5	11.2	-7.3
Pharmaceuticals	500.2	492.1	-8.1	-1.6%	-8.4	0.4	-0.1
Others & Adjustments	56.8	51.1	-5.6	-9.9%	0.0	-5.6	0.0
Total	2,190.5	2,318.6	128.1	5.8%	14.6	124.6	-11.1

Analysis






Core Operating Income by Business segment

Unit; billions of yer								
	FY2017	FY2018	Difference	Price Variance	Cost Variance	Shipping Volume Variance and Other	Total	
Petrochemicals & Plastics	94.6	61.6	-33.0	-6.0	1.0	-28.0	-33.0	
Energy & Functional Materials	19.2	23.0	3.8	-2.5	-3.5	9.8	3.8	
IT-related Chemicals	12.3	26.2	13.9	-10.5	10.0	14.4	13.9	
Health & Crop Sciences	44.0	19.7	-24.2	-9.5	-4.0	-10.7	-24.2	
Pharmaceuticals	94.8	80.8	-14.0	-8.4	3.5	-9.1	-14.0	
Others & Adjustments	-2.2	-7.0	-4.9	0.0	0.0	-4.9	-4.9	
Total	262.7	204.3	-58.4	-36.9	7.0	-28.5	-58.4	


Analysis



SUMİTOMO CHEMICAL



Core Operating Income Total ¥61.6 billion (-33.0 from FY2017)







Core Operating Income Total ¥23.0 billion (+3.8 from FY2017)





IT-related Chemicals - Segment Analysis -




Core Operating Income Total ¥26.2 billion (+13.9 from FY2017)







Core Operating Income Total ¥19.7 billion (-24.2 from FY2017)




Price variance	 Decrease in profit margin on feed additive
-9.5	methionine
Cost variance	 Launch of new production line for feed additive
-4.0	methionine
Volume variance etc.	 Decrease in shipment of crop protection chemicals
-10.7	in North America due to frequent extreme weather Equity method investment loss on Nufarm



Pharmaceuticals - Segment Analysis -



Core Operating Income Total ¥80.8 billion (-14.0 from FY2017)





	FY2017	FY2018	Difference
Impairment loss	-12.4	-24.6	-12.3
Restructuring charges	-14.2	-9.1	5.1
Changes in fair value of contingent consideration	6.1	9.0	2.8
Reversal of impairment loss	3.5	3.0	-0.5
Gain on sale of property, plant and equipment	6.8	1.4	-5.4
Others	-1.6	-0.9	0.7
Non-recurring items	-11.8	-21.3	-9.5



Consolidated Balance Sheets

							lions of yen
	31-Mar-18	31-Mar-19	Difference		31-Mar-18	31-Mar-19	Difference
Current assets	1,254.8	1,291.2	36.4	Liabilities	1,816.5	1,819.7	3.3
Cash and cash equivalents	231.9	201.7	-30.3	Trade and other payables	486.8	482.9	-4.0
Trade and other receivables	530.6	550.0	19.4	Interest-bearing Liabilities	842.2	839.5	-2.6
Inventories	446.8	489.3	42.5	Others	487.5	497.3	9.9
Others	45.5	50.3	4.8	Equity	1,252.2	1,351.9	99.7
Non-current assets	1,813.9	1,880.4	66.5	Shareholders' equity	842.0	922.3	80.3
Property, plant and equipment	675.7	735.9	60.2	Other components of equity	85.2	76.4	-8.7
Goodwill and Intangible assets	355.5	343.5	-12.0	Non-controlling interests	325.1	353.2	28.1
Others	782.6	801.0	18.3				
Total	3,068.7	3,171.6	102.9	Total	3,068.7	3,171.6	102.9
				Equity attributable to owners of parent to total assets	30.2%	31.5%	1.3%
				D/E ratio (times)	0.7	0.6	-0.1



Consolidated Statements of Cash Flows

Unit; billions of y					
	FY2017	FY2018	Difference		
Cash flows from operating activities	293.3	208.1	-85.1		
Cash flows from investing activities	-154.5	-180.8	-26.3		
Free cash flows	138.7	27.3	-111.4		
Cash flows from financing activities	-94.3	-60.9	33.4		
Effect of exchange rate changes on cash and cash equivalents	-5.8	3.3	9.1		
Net change in cash and cash equivalents	38.6	-30.3	-68.9		
Cash and cash equivalents at end of year	231.9	201.7	-30.3		



2. Outlook for FY2019




	FY2018	FY2019 (estimated)	Difference	Ratio
Sales revenue	2,318.6	2,440.0	121.4	5.2%
Core operating income	204.3	205.0	0.7	0.4%
(Equity in earnings)	(37.2)	(23.0)	(-14.2)	-
(Non-recurring items)	(-21.3)	(-15.0)	(6.3)	-
Operating income	183.0	190.0	7.0	3.8%
Net income attributable to owners of the parent	118.0	100.0	-18.0	-15.2%
ROE	12.3%	9.7%		
Exchange rate(yen/\$)	110.92	110.00		
Naphtha price(yen/KL)	49,500	43,000		



Sales revenue by Business segment


	FY2018	FY2019 (estimated)	Difference	Ratio	Sales Price Variance	Shipping Volume Variance	Foreign Currency Conversion Variance
Petrochemicals & Plastics	757.5	765.0	7.5	1.0%	-65.0	75.2	-2.7
Energy & Functional Materials	282.9	310.0	27.2	9.6%	3.5	22.9	0.8
IT-related Chemicals	396.8	425.0	28.2	7.1%	-29.5	51.4	6.3
Health & Crop Sciences	338.1	390.0	51.9	15.4%	-1.5	55.1	-1.7
Pharmaceuticals	492.1	495.0	2.9	0.6%	0.0	2.9	0.0
Others & Adjustments	51.1	55.0	3.9	7.6%	0.0	3.9	0.0
Total	2,318.6	2,440.0	121.4	5.2%	-92.5	211.2	2.7

Analysis



Core Operating Income by Business segment


	FY2018	FY2019 (estimated)	Difference	Price Variance	Cost Variance	Shipping Volume Variance and Other	Total
Petrochemicals & Plastics	61.6	40.0	-21.6	-15.0	-0.5	-6.1	-21.6
Energy & Functional Materials	23.0	25.0	2.0	-3.5	-1.0	6.5	2.0
IT-related Chemicals	26.2	27.0	0.8	-28.5	6.0	23.3	0.8
Health & Crop Sciences	19.7	37.0	17.3	0.0	-4.5	21.8	17.3
Pharmaceuticals	80.8	81.0	0.2	0.0	2.0	-1.8	0.2
Others & Adjustments	-7.0	-5.0	2.0	0.0	0.0	2.0	2.0
Total	204.3	205.0	0.7	-47.0	2.0	45.7	0.7



SUMİTOMO CHEMICAL




Core Operating Income Total ¥40.0 billion (-21.6 from FY2018)







Core Operating Income Total ¥25.0 billion (+2.0 from FY2018)





IT-related Chemicals - Segment Analysis -




Core Operating Income Total ¥27.0 billion (+0.8 from FY2018)







Core Operating Income Total ¥37.0 billion (+17.3 from FY2018)






Pharmaceuticals - Segment Analysis -



Core Operating Income Total ¥81.0 billion (+0.2 from FY2018)





	Unit; billions of yen			
	FY2018	FY2019 (estimated)	Difference	
Cash flows from operating activities	208.1	220.0	11.9	
Cash flows from investing activities	-180.8	-340.0	-159.1	
Free cash flows	27.3	-120.0	-147.3	
Cash flows from financing activities	-60.9	165.0	225.9	
Effect of exchange rate changes on cash and cash equivalents	3.3	0.0	-3.3	
Net change in cash and cash equivalents	-30.3	45.0	75.2	
Interest-bearing debt balance	839.5	1,050.0	210.5	



(Reference: Segment Information)



Segment Topics

Petrochemicals & Plastics	 Started the shipment of products from the Rabigh Phase 2 Project Decided to restart a Methyl Methacrylate production line in Singapore
Energy & Functional Materials	 Expanded production capacity for Polyether Sulfone (PES) Decided to expand production capacity for cathode materials (Tanaka Chemical Corp.)
IT-related Chemicals	 Expanded production capacity for high-purity chemicals for semiconductors in China (Changzhou/Xi'an) A polarizing film manufacturing company in China became a wholly owned subsidiary Acquired shares of JOLED
Health & Crop Sciences	 Completed construction of a new production line for feed additive methionine Decided to merge group companies in India Expanded R&D facilities (CRC in Takarazuka, BRC in VBC)
Pharmaceuticals	 Resolution of disputes under a consolidated patent infringement lawsuit regarding ANDAs for LATUDA in the U.S. (One case is pending) Efforts toward regenerative medicine through collaboration with Kyoto University's Center for iPS Cell Research and Application (CiRA).
	SUMİTOMO CHEMICAL

	FY2017			FY2018				FY2019 (e	estimated)	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1st Half	2nd Half
Petrochemicals & Plastics	153.5	166.6	176.5	177.5	185.6	194.8	196.5	180.6	385.0	380.0
Energy & Functional Materials	59.6	60.6	67.5	63.2	68.5	72.3	73.8	68.2	150.0	160.0
IT-related Chemicals	90.8	97.8	98.1	82.1	89.2	106.3	105.5	95.9	210.0	215.0
Health & Crop Sciences	67.5	70.2	78.5	123.5	69.4	68.8	74.5	125.4	165.0	225.0
Pharmaceuticals	124.6	123.5	132.3	119.8	124.3	118.4	129.1	120.3	245.0	250.0
Others & Adjustments	12.0	13.7	12.6	18.5	11.9	12.7	12.6	14.0	25.0	30.0
Total	507.9	532.4	565.5	584.6	548.9	573.2	592.0	604.4	1,180.0	1,260.0



	FY2017			FY2018				FY2019 (e	estimated)	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1st Half	2nd Half
Petrochemicals & Plastics	15.0	26.8	28.9	23.9	17.8	17.6	16.4	9.8	19.0	21.0
Energy & Functional Materials	4.8	5.5	5.6	3.3	5.9	6.9	7.4	2.8	12.5	12.5
IT-related Chemicals	3.3	5.7	4.6	-1.2	4.3	10.5	7.5	3.9	13.5	13.5
Health & Crop Sciences	5.5	2.9	10.3	25.3	2.6	-0.2	1.5	15.8	0.0	37.0
Pharmaceuticals	25.9	32.2	23.5	13.2	19.7	19.6	20.0	21.5	40.0	41.0
Others & Adjustments	-1.1	0.4	-0.9	-0.5	-2.1	-0.6	0.1	-4.4	-5.0	0.0
Total	53.5	73.5	71.8	63.8	48.2	53.9	52.8	49.3	80.0	125.0



	FY2017	FY2018	FY2019 (estimated)
Capital Expenditures	158.8	163.7	153.0
Depreciation and Amortization	107.1	112.5	135.0
Research & Development Expenses	165.3	163.5	175.0
Number of Employees (as of March 31)	31,837	32,542	34,000



	FY2017	FY2018	Difference
Petrochemicals & Plastics	17.4	31.5	14.1
Energy & Functional Materials	22.5	24.3	1.8
IT-related Chemicals	24.5	33.6	9.1
Health & Crop Sciences	56.3	39.9	-16.4
Pharmaceuticals	21.2	16.9	-4.4
Others & Adjustments	16.8	17.6	0.7
Total	158.8	163.7	4.8



			Unit; billions of yen
	FY2018	FY2019 (estimated)	Difference
Petrochemicals & Plastics	31.5	29.5	-2.0
Energy & Functional Materials	24.3	31.0	6.7
IT-related Chemicals	33.6	44.0	10.5
Health & Crop Sciences	39.9	18.5	-21.4
Pharmaceuticals	16.9	13.0	-3.9
Others & Adjustments	17.6	17.0	-0.6
Total	163.7	153.0	-10.7



		I	Jnit; billions of yen
	FY2017	FY2018	Difference
Petrochemicals & Plastics	23.0	22.0	-0.9
Energy & Functional Materials	13.9	15.4	1.5
IT-related Chemicals	29.6	31.1	1.5
Health & Crop Sciences	16.2	18.7	2.5
Pharmaceuticals	15.1	16.3	1.2
Others & Adjustments	9.4	9.0	-0.4
Total	107.1	112.5	5.4



	FY2018	FY2019 (estimated)	Difference
Petrochemicals & Plastics	22.0	26.5	4.5
Energy & Functional Materials	15.4	16.0	0.6
IT-related Chemicals	31.1	34.5	3.4
Health & Crop Sciences	18.7	25.5	6.8
Pharmaceuticals	16.3	19.5	3.2
Others & Adjustments	9.0	13.0	4.0
Total	112.5	135.0	22.5



	FY2017	FY2018	Difference
Petrochemicals & Plastics	6.6	7.1	0.4
Energy & Functional Materials	7.5	8.5	1.0
IT-related Chemicals	17.3	17.3	-0.0
Health & Crop Sciences	29.3	29.3	0.0
Pharmaceuticals	89.3	85.1	-4.3
Others & Adjustments	15.3	16.2	0.9
Total	165.3	163.5	-1.9





	FY2018	FY2019 (estimated)	Difference
Petrochemicals & Plastics	7.1	7.5	0.4
Energy & Functional Materials	8.5	8.5	0.0
IT-related Chemicals	17.3	18.0	0.7
Health & Crop Sciences	29.3	34.0	4.7
Pharmaceuticals	85.1	89.0	3.9
Others & Adjustments	16.2	18.0	1.8
Total	163.5	175.0	11.5



	Sales Revenue			
Company	FY2017	FY2018	Profit Trends	
The Polyolefin Company (Singapore) (millions of USD)	1,179	1,146	Decreased margins and decreased sales volume due to periodic plant maintenance in the current term.	
Petrochemical Corporation of Singapore (millions of USD)	2,692	2,770	Decreased margins and decreased sales volume due to periodic plant maintenance in the current term.	
Rabigh Refining and Petrochemical Company (millions of SAR)	34,211	40,998	Lower margin on oil refining.	
Dongwoo Fine-Chem (billions of KRW)	2,160.8	2,383.2	Increased due to higher sales volume and other factors despite lower selling price.	
Valent U.S.A. and Subsidiaries (millions of USD)	915	848	Weather conditions have created market delays and reduced market opportunities.	









Interest-bearing Liabilities / D/E Ratio Transition

